New standards and new constraints redefine treatment sequencing in platinum-resi

New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer

Ray-Coquard I, Moore KN

Nat Rev Clin Oncol . 2026 Jun 17

PMID: 42310471

ABSTRACT

Conflict of interest statement
Competing interests: I.R.C. is a scientific advisory board member and/or consultant for Abbvie, Agenus, Antares, AstraZeneca, BMS, BioNTech, BeOne, Corcept, Daiichi-Sankyo, Deciphera, ESAI, Genmab, GSK, Immunocore, Incyte, Janssen, Lilly, Macrogenics, Merck, Novartis, OSE Pharma, Pharma&, Pfizer, Regeneron, Tubulis, Verastem and Zentalis; and has had leadership roles with ENGOT Network (Chair), ESGO (Council member) and GINECO group (past Chair). K.N.M. is a scientific advisory board member and/or consultant for Aadi, Abbvie, AstraZeneca, BioNTech, BeOne, Corcept, Caris, Daiichi-Sankyo, Genmab, GSK, Immatics, Immunocore, Immunogen, Incyte, Janssen, Merck, Regeneron, Schrodinger, Takeda, Tubulis, Verastem, Whitehawk, Zentalis and Zymeworks; has developed educational content and/or been a speaker for Oncology Learning Network, Physicians Education Resource, PRIME and Research to Practice; and has had leadership roles with ASCO (Board of Directors and Treasurer), GOG Foundation (Board of Directors), GOG Partners (Associate Director) and NRG (Ovarian Committee Chair).

Chargement en cours...